Viking Therapeutics Stock Slides After Company Misses Q2 Earnings Estimates Viking Therapeutics shares fall in Wednesday's after-hours session after the company reported financial results for the second quarter.
Viking Therapeutics Inc (NASDAQ:VKTX) Posts Wider Q2 2025 Loss, Shares Drop in After-Hours Trading Viking Therapeutics reports wider Q2 2025 loss, missing EPS estimates, causing a 5.7% after-hours dip. Focus remains on clinical pipeline progress amid revenue challenges.
Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment? The company announced a new drug that uses the same mechanism as Eli Lilly's retatrutide.
3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking Timing matters with biotech stocks; these three companies offer distinct risk-reward profiles but have upcoming catalysts that could redefine their value
Why Viking Therapeutics, 67% Off Its Recent Highs, Could Still Have An Edge In Obesity The company just initiated two Phase 3 studies of its weekly under-the-skin shot to stoke weight loss.
What's Going On With Viking Therapeutics Stock On Wednesday? Viking Therapeutics begins Phase 3 trials for VK2735, testing weekly injections in over 5,000 adults with obesity or type 2 diabetes over 78 weeks.
